Neumora Therapeutics, Inc. — Q3 2023 Form 10-Q
Business context and reporting period
Unaudited results for the quarter and nine months ended September 30, 2023. Neumora is a clinical-stage biopharmaceutical company with seven clinical and preclinical neuroscience programs. It has no approved products and has not generated product revenue.
The company completed its IPO on September 19, 2023, selling 14.71 million shares at $17.00 per share and reporting net proceeds of $226.6 million. Its preferred shares converted into common stock at the IPO. The company also effected a 7.8463-for-1 reverse stock split.
Financial performance and liquidity
- Revenue and margins: No product revenue; therefore, operating margins are not meaningful. The filing reports no clear recurring revenue source from product sales.
- Q3 2023: Operating expenses were $56.9 million, including R&D of $41.6 million and G&A of $15.3 million. Net loss was $53.0 million, or $1.14 per share, versus a $29.3 million loss, or $1.06 per share, in Q3 2022.
- Nine months: Operating expenses totaled $138.1 million and net loss was $127.2 million, or $3.59 per share, versus expenses of $105.2 million and a net loss of $102.8 million, or $3.83 per share, in the comparable 2022 period. 2022 expenses included $13.0 million of acquired in-process R&D; 2023 did not.
- Cash and liquidity: Cash, cash equivalents and marketable securities totaled $519.5 million at September 30, 2023. Management stated this should fund operations and capital needs for at least 12 months following issuance of the financial statements.
- Cash flow: Nine-month operating cash use was $111.8 million, compared with $84.5 million in 2022. Investing activities provided $50.7 million, largely from marketable-security maturities and sales; financing activities provided $232.4 million, primarily from the IPO.
- Debt and liabilities: The filing does not report interest-bearing debt. Total liabilities were $32.1 million, including $6.1 million of operating lease liabilities and $23.3 million of accrued liabilities.
Material changes versus the prior comparable period
- Q3 R&D expense increased 84% year over year, mainly from navacaprant Phase 3 start-up activities, NMRA-511 clinical work, and higher internal and vendor costs. Nine-month R&D increased 52%.
- Q3 G&A expense increased 90%, and nine-month G&A increased 43%, reflecting higher personnel and stock-based compensation, professional services, and public-company costs.
- Higher interest income partly offset the greater operating loss: $3.8 million for Q3 2023 versus $1.4 million in Q3 2022, and $11.0 million for the first nine months versus $2.3 million.
- Cash and marketable securities increased substantially with IPO proceeds; the company reported an accumulated deficit of $594.7 million at quarter-end.
Outlook, risks, contingencies and unusual items
- Management expects expenses and operating losses to increase as it advances programs, expands clinical development, hires personnel and operates as a public company. It expects to need additional financing for its long-term plan; future financing may be dilutive or unavailable on acceptable terms.
- Navacaprant is in a pivotal Phase 3 program for moderate-to-severe major depressive disorder. Management anticipated KOASTAL-1 topline results in the second half of 2024 and planned multiple trial initiations across programs over the following 12–18 months.
- In October 2023, a $90.0 million BlackThorn milestone became due after the first patient was dosed in the navacaprant Phase 3 trial; it may be settled in cash, stock, or a combination. A separate $2.0 million Vanderbilt development milestone also became due and was expected to be paid in Q4 2023.
- Additional contingent payments, royalties and sublicense obligations may arise under acquisition and license agreements, including substantial development and commercial milestones. These amounts are generally dependent on future events and were not reported as due at September 30, except as subsequently noted.
- Key risks include clinical and regulatory failure, dependence on third-party research and manufacturing, intellectual-property protection, financing needs, and potential trial, supply-chain or regulatory disruption. The filing says risk factors were not materially changed from the IPO prospectus. No material legal proceedings were reported.
Important facts for investors to verify
- Whether navacaprant Phase 3 enrollment, execution and KOASTAL-1 timing remain on track, and whether later clinical results support the program.
- Cash burn against the stated minimum 12-month runway, including the $90.0 million and $2.0 million milestones and other upcoming clinical or contractual obligations.
- How the company funds its expanding pipeline beyond the stated runway, and the potential dilution or terms of future financing.
- Actual timing and costs of planned trials and data readouts across the seven programs, alongside growth in R&D and G&A expenses.
- Potential future milestone, royalty and sublicense liabilities under the BlackThorn, Vanderbilt, Amgen and other agreements.